根据 SPARTAN 和 TITAN 研究，阿帕鲁胺被批准用于治疗非转移性去势抵抗性和转移性去势敏感型前列腺癌患者。皮疹是各种适应症的常见不良反应。我们假设早期识别和干预可以改善皮疹结果。向参加 Apa-RP (NCT04523207) 的所有患者提供了预先指定的皮疹管理指南，概述了推荐的皮肤护理实践。 Apa-RP 的皮疹相关安全数据与 SPARTAN 和 TITAN 的数据进行了描述性比较。与 SPARTAN 和 TITAN 中的患者相比，Apa-RP 患者的皮疹相关结果有所改善。提高警惕和主动管理可能会降低发病率、严重程度和风险。阿帕鲁胺治疗期间皮疹的持续时间。© 2024。作者。

Based on the SPARTAN and TITAN studies, apalutamide is approved for patients with nonmetastatic castration-resistant and metastatic castration-sensitive prostate cancer. Skin rash was a common adverse reaction across indications. We hypothesized that earlier identification and intervention could improve rash outcomes.A prespecified rash management guide outlining recommended skin care practices was provided to all patients enrolled in Apa-RP (NCT04523207). Rash-related safety data from Apa-RP were compared descriptively with data from SPARTAN and TITAN.Patients in Apa-RP experienced improved rash-related outcomes vs those in SPARTAN and TITAN.Increased vigilance and proactive management may reduce the incidence, severity, and duration of rash during apalutamide treatment.© 2024. The Author(s).